Colin Marshall

Dr. Colin Marshall is a Senior Research Fellow in the Department of Chemistry within the School of Natural and Computing Sciences at the University of Aberdeen. His research is focused on the synthesis and application of novel organic compounds for the treatment of neurodegenerative diseases, particularly Alzheimer’s disease and related tauopathies.

His research interests lie at the intersection of medicinal chemistry, organic synthesis, and structural biology. He specializes in the design and characterization of diaminophenothiazinium compounds such as methylthioninium chloride (MTC), which inhibit tau protein aggregation—a key pathological feature in Alzheimer’s disease. His work includes both synthetic methodology development and biochemical evaluation of therapeutic candidates.

The trend in his publications from 2004 to 2015 reflects a strong trajectory in drug discovery for neurodegenerative conditions, with a shift from fundamental organometallic and heterocyclic chemistry toward applied biomedical research. His later works emphasize cellular modeling, proteolysis mechanisms, and translational therapeutic development.

Dr. Marshall has contributed to multiple patents and peer-reviewed articles, demonstrating innovation and intellectual property generation in pharmaceutical chemistry. While no formal awards are listed, his sustained contribution to high-impact therapeutic research underscores significant scientific engagement.

• Senior Research Fellow, University of Aberdeen
• Active researcher in medicinal and synthetic chemistry
• Extensive collaboration with experts in neurodegeneration

Dr. Marshall has not publicly listed any PhD or Master’s students. However, his involvement in fellowship opportunities and research groups suggests mentorship within collaborative projects. His work is associated with advanced research facilities at Aberdeen, particularly in synthetic and analytical chemistry. He contributes to research groups focused on energy, sustainability, and computational modeling, indicating interdisciplinary engagement. Future work likely continues in optimizing neuroprotective compounds and elucidating their mechanisms of action.